ArticleJAC-antimicrobial resistance2026
Epidermicin NI01 demonstrates potent
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: In the UK, over 16% of antibiotic prescriptions are for skin infections. New approaches are required to treat and prevent such infections, and new therapeutic modalities should be investigated. Epidermicin NI01 is a first-in-class bacteriocin with potent activity and a novel mode of action against MRSA and Streptococci, leading causes of community and healthcare acquired skin infections and a significant burden of antimicrobial resistance (AMR). The activity of NI01 in a model of MRSA skin infection was assessed during this study. Methods: Immunosuppressed male CD1 mice were wounded dorsally using tape-stripping and Results: There were no adverse effects observed due to infection or treatment. No reduction in skin burden was seen in the 3% NI01 mono-dose group. Treatments resulted in significant log Conclusions: These
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.